An Analysis of the tnAcity Trial

Adam Brufsky, MD, PhD, FACP, discusses the tnAcity trial, which is aimed to clarify how best to use existing drugs in patients with triple-negative breast cancer.

Adam Brufsky, MD, PhD, FACP, professor of medicine, associate division chief, Division of Hematology/Oncology, University of Pittsburgh School of Medicine, discusses the tnAcity trial, which is aimed to clarify how best to use existing drugs in patients with triple-negative breast cancer (TNBC).

Clinical Pearls:

  • The tnAcity trial will measure the efficacy of combinations, such as gemcitabine and carboplatin, carboplatin and nab-paclitaxel (Abraxane), and gemcitabine and nab-paclitaxel
  • During this phase II trial, which has about 80 patients enrolled, patients will be randomized to receive one of the three combinations
  • Based on the results of the phase II trial, the two combinations that prove to be the most effective will be tested further
  • The trial will also investigate biomarkers that will help physicians figure out how to optimally treat patients with TNBC